Navigating uncertainty: the future of vaccine oversight...
The evolving landscape of vaccine oversight makes it key to maintain public trus...
Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Kymera’s programme focuses on removing CDK2 from cells compared to other therapi...
Novartis concludes Regulus Therapeutics acquisition
Novartis has completed its previously announced acquisition of Regulus Therapeut...